Market data loadingS&P 500--NASDAQ--Data as of latest ETNo timestamp

Absci Corporation (ABSI) Financial Statements

Absci Corporation (ABSI) reported trailing twelve-month revenue of $1.6M (down 62.3% year on year) and net income of -$121.1M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: -$109.0M.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

ABSIAbsci CorporationFollow ABSI — free
Biotechnology · Healthcare
—
Price chart with a free account
Market cap
1.6B
P/E TTM
—
Dividend yield
—
52-week
—
Next earnings
12 Nov, in 19 days

Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.

LineFY2021
Dec 21
FY2022
Dec 22
FY2023
Dec 23
FY2024
Dec 24
FY2025
Dec 25
TTM
Jun 26
Trend
Revenue4.04.55.74.52.81.6
Research & development44.658.948.163.981.486.5
Operating income-75.2-106.8-115.5-108.9-120.3-126.2
Pre-tax income-109.9-105.4-110.5-103.0-115.1-121.1
Income tax-8.9-0.50.10.10.10.0
Net income-101.0-104.9-110.6-103.1-115.2-121.1
Diluted EPS ($)-2.08-1.15-1.20-0.94-0.84-0.76
Diluted shares (mn)49.790.892.0110.2136.8—

USD millions · SEC XBRL

Absci Corporation — questions

What is Absci Corporation's revenue?
$1.6M over the twelve months to 2026-06-30, down 62.3% year on year, from its 10-Q and 10-K filings.
What is Absci Corporation's net income?
-$121.1M over the twelve months to 2026-06-30.
What is Absci Corporation's free cash flow?
-$109.0M over the twelve months to 2026-06-30.
What are Absci Corporation's diluted earnings per share?
$-0.76 over the twelve months to 2026-06-30.

Every figure on this page comes from Absci Corporation's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.